

SENATE COMMITTEE ON HEALTH POLICY

March 23, 2005
1:00 P.M.

Hearing Room B
Tapes 45 - 46

MEMBERS PRESENT: **Sen. Laurie Monnes Anderson, Chair**
 Sen. Jeff Kruse, Vice-Chair
 Sen. Peter Courtney
 Sen. Bill Morrisette

MEMBER EXCUSED: **Sen. Gary George**

STAFF PRESENT: **Rick Berkobien, Committee Administrator**
 Brittany Kenison, Committee Assistant

MEASURES/ISSUES HEARD:
 SB 962 – Public Hearing
 SB 783 – Public Hearing
 SB 784 – Public Hearing

These minutes are in compliance with Senate and House Rules. Only text enclosed in quotation marks reports a speaker's exact words. For complete contents, please refer to the tapes.

<u>TAPE/#</u>	<u>Speaker</u>	<u>Comments</u>
TAPE 45, A		
003	Chair Monnes Anderson	Calls the meeting to order at 1:03 p.m. Opens public hearing on SB 962.
<u>SB 962 – PUBLIC HEARING</u>		
010	Rep. Vicki Berger	House District 20. Testifies in support of SB 962.
035	Rick Berkobien	Committee Administrator. Explains the bill and introduces the -1 amendments (EXHIBIT A).
050	Sarah Doll	Program Director, Oregon Environmental Council. Submits and presents written testimony in support of SB 962 (EXHIBIT B).
070	Chair Monnes Anderson	Asks where the report is regarding the study performed on dust.
071	Doll	Answers question. Continues testifying in support of SB 962.
095	Chair Monnes Anderson	Asks to clarify what chemicals Europe has banned.
096	Doll	Answers question.
100	Wendy Marich	Citizen, Oregon. Testifies in support of SB 962.
129	Chair Monnes Anderson	Stands the committee at ease.
135	Chair Monnes Anderson	Reconvenes the meeting.
140	Jim Marquee	American Chemistry Council. Introduces Susan Landry and Ray Dawson.
150	Susan Landry	Advisor, Fire Safety & Advocacy, Albemarle Corporation. Submits and presents written testimony in opposition to SB 962 (EXHIBIT C), a PowerPoint presentation on “Deca-BDE Regulatory and Environmental Issues” (EXHIBIT D) and a fact sheet about Flame Retardants (EXHIBIT E).
160	Landry	Continues discussing PowerPoint presentation on Deca-BDE

200	Landry	Regulatory & Environmental Issues. Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.
255	Landry	Summarizes and concludes.
260	Ray Dawson	Bromine Science and Environmental Forum, Washington D.C. Continues on page 13 of the PowerPoint presentation of EXHIBIT D. Submits written testimony in opposition to SB 962 (EXHIBIT F) and an informational packet on Polybrominated Diphenyl Ethers (PBDEs) on behalf of Donald Moulds, Director, Senate Office of Research, Sacramento, California (EXHIBIT G) .
298	Chair Monnes Anderson	Asks Dawson to comment on previously banned chemicals in Europe.
300	Dawson	Defers to later in the presentation. Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.
330	Chair Monnes Anderson	Asks to clarify why testing is mostly being performed in Europe.
335	Dawson	Provides explanation. Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.
385	Dawson	Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.
405	Chair Monnes Anderson	Asks Dawson to comment on Penta and Octa chemicals.
410	Dawson	Provides explanation. Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.
<u>TAPE 46, A</u>		
005	Sen. Kruse	Asks Marquee if he would be supportive of the bill with the -1 amendments.
010	Marquee	Discusses why they oppose the bill overall.
025	Sen. Kruse	Thanks the panel for the information.
040	Jennifer Kimball	Citizen, Marion County, Oregon. Testifies in support of SB 962.
060	Janie Huff-Slankard	Pediatric Nurse Practitioner. Oregon Pediatric Nurse Practitioner Association. National Association for Pediatric Nurse Practitioners. The American Academy of Pediatrics. Submits and presents written testimony in support of SB 962 (EXHIBIT H) .
070	Chair Monnes Anderson	Asks for studies that Huff-Slankard refers to.
071	Huff-Slankard	Offers to return information to the committee. Continues to review testimony in support of SB 962.
125	Kim Hooper	Ph.D., Hazardous Materials Laboratory, Berkeley, California. Submits and presents PowerPoint presentation in support of SB 962 (EXHIBIT I) .
175	Chair Monnes Anderson	Asks to verify and explain studies performed as discussed in his testimony.
177	Hooper	Explains. Continues testimony.
207	Chair Monnes Anderson	Asks to clarify that Deca breaks down rapidly.
208	Hooper	Answer, yes. Explains.
228	Chair Monnes Anderson	Asks if a study has been performed with Deca broken down on mice.
230	Hooper	Answers question. Continues to discuss PowerPoint presentation on "Deca-BDE: Why are we concerned?"

280	Chair Monnes Anderson	Asks to comment on Europe's statement two days prior regarding Deca.
283	Hooper	Defers answer to later in presentation. Continues presentation.
325	Chair Monnes Anderson	Asks why California has not banned Deca.
327	Hooper	Speculates.
335	Sen. Morrisette	Asks if Washington has banned Deca.
336	Hooper	Answers question.
337	Sen. Morrisette	Asks if other states have banned Deca.
340	Hooper	States that he does not know. Discusses how Deca enters into the human system.
350	Catherine Thomasson	Physician, Internal Medicine. President, Oregon Chapter of Physicians for Social Responsibility. States that Maine has banned Deca. Submits informational packet on Deca-BDE in support of SB 962 (EXHIBIT J). Reviews PowerPoint presentation about Deca-BDE.
438	Chair Monnes Anderson	Asks to clarify that the statistics Thomasson refers to include polybrominated diphenyl ethers (PBDEs).
440	Thomasson	Responds.
TAPE 45, B 006	Chair Monnes Anderson	Asks if Deca-BDE is part of a Polychlorinated Biphenyls (PCB).
080	Thomasson	Responds.
010	Sen. Morrisette	Asks if PBDEs is the same as Deca-BDE.
012	Thomasson	Answers question.
014	Sen. Morrisette	Comments on the three categories of chemicals in the bill and remarks that there has been an amendment introduced to exclude Deca from the bill. Asks to the clarify article that he read in the Oregonian.
020	Thomasson	Responds.
021	Hooper	Adds further explanation.
022	Sen. Morrisette	Refers to same article in the Oregonian. Asks what the article means by "restrictions of the chemicals" of PBDEs.
023	Thomasson	Clarifies that only Deca is banned in Maine.
025	Chair Monnes Anderson	States that it will be addressed later.
028	Thomasson	Comments that states have been phasing out the chemicals. Continues reviewing PowerPoint presentation on Deca-BDE.
043	Chair Monnes Anderson	Clarifies the study that Thomasson referred to.
045	Thomasson	Answers question.
046	Chair Monnes Anderson	States that she would interested if blind studies were performed.
047	Hooper	Clarifies that controlled studies were performed. Elaborates.
053	Thomasson	Continues reviewing PowerPoint presentation on Deca-BDE. Discusses alternatives.
080	Chair Monnes Anderson	Asks if Thomasson is aware of information from a study that takes Deca from the 2006 ban.
083	Thomasson	Discusses her understanding. Continues discussing alternatives.
110	Chair Monnes Anderson	Asks if much research has been performed on ammonium and aluminum.
112	Thomasson	Defers answer to later in the presentation.
150	Thomasson	Summarizes and concludes.

165 Kathleen Diane Drum Oregon Nurses Association (ONA). Member, Health Policy Cabinet Public Health Nurse. Maternal-Child Health. Submits and presents written testimony in support of SB 962 (**EXHIBIT K**) and a report on “Neurobehavioral Derangements in Adult Mice Receiving Decabrominated Diphenyl Ether (PBDE 209) during a Defined Period of Neonatal Brain Development” (**EXHIBIT L**).

215 Drum Continues to testify in support of SB 962.

265 Drum Summarizes and concludes.

290 Rhett Lawrence Environmental Advocate, Oregon State Public Interest Research Group (OSPIRG). Submits and presents written testimony in support of SB 962 (**EXHIBIT M**).

340 Drum Comments that mothers in Oregon have the highest levels of PBDEs in their breast milk in the nation and in the world.

360 Myrna Soule Hearing Disability Association of Oregon. Testifies in support of SB 962.

420 Amelia Psmythe Executive Director, Nursing Mothers Counsel of Oregon. Submits and presents written testimony regarding SB 962 (**EXHIBIT N**).

TAPE 46, B

010 Gail Shibley Administrator, Health Services, Office of Public Health Systems, Oregon Department of Human Services. Submits and presents written testimony with a neutral position on SB 962 (**EXHIBIT O**).

018 Sen. Kruse States that the legislature should proceed with caution. Comments on a book written by Rachael Green called Silent Spring.

The following material is submitted for the record without public testimony:

Bob Livingston Legislative Director, Oregon State Fire Fighters Council. Submits written testimony in support of SB 962 (**EXHIBIT P**).

035 Chair Monnes Anderson Closes the public hearing on SB 962 and opens a public hearing on SB 783 and SB 784.

SB 783, SB 784 – PUBLIC HEARING

040 Rick Berkobien Committee Administrator. Explains SB 783 and SB 784 and introduces the -1 amendments to SB 783 (**EXHIBIT Q**) and the -1 amendments to SB 784 (**EXHIBIT R**).

050 Sen. Bill Morrisette Senate District 6. Testifies in support of SB 783 and SB 784.

085 Deborah Turner Chairperson, Government and Public Affairs Committee, Oregon State Assembly of the Association of Surgical Technologies, Inc. Submits and presents written testimony in support of SB 784 (**EXHIBIT S**) and in support of SB 783 (**EXHIBIT T**).

155 Chair Monnes Anderson Asks Turner if she assisted in Sen. Morrisette’s operation.

157 Turner Responds, yes.

162 Sen. Morrisette Comments on his procedure.

175 Adam Perryman President, Oregon State Assembly of the Association of Surgical Technologists. Submits and presents written testimony in support of SB 783 and SB 784 (**EXHIBIT U**).

225 Perryman Continues to testify in support of SB 783 and SB 784.

285 Turner Testifies in support of SB 783.

355 Chair Monnes Anderson Closes the public hearing on SB 783 and SB 784. Adjourns meeting at 2:56 p.m.

EXHIBIT SUMMARY

- A. SB 962, -1 amendments, staff, 1 p**
- B. SB 962, written testimony, Sarah Doll, 6 pp**
- C. SB 962, written testimony, Susan Landry, 2 pp**
- D. SB 962, PowerPoint presentation, Susan Landry, 24 pp**
- E. SB 962, fact sheet, Susan Landry, 8 pp**
- F. SB 962, written testimony, Raymond Dawson, 3 pp**
- G. SB 962, informational packet from Donald Moulds, Raymond Dawson, 20 pp**
- H. SB 962, written testimony, Janie Huff-Slankard, 1 p**
- I. SB 962, PowerPoint presentation, Kim Hooper, 3 pp**
- J. SB 962, informational packet, Catherine Thomasson, 8 pp**
- K. SB 962, written testimony, Kathleen Drum, 3 pp**
- L. SB 962, report, Kathleen Drum, 9 pp**
- M. SB 962, written testimony, Rhett Lawrence, 5 pp**
- N. SB 962, written testimony, Amelia Psmythe, 1 p**
- O. SB 962, written testimony, Gail Shibley, 2 pp**
- P. SB 962, written testimony, Bob Livingston, 1 p**
- Q. SB 783, -1 amendment, staff, 3 pp**
- R. SB 784, -1 amendment, staff, 4 pp**
- S. SB 784, written testimony, Deborah Turner, 5 pp**
- T. SB 783, written testimony, Deborah Turner, 6 pp**
- U. SB 783, SB 784, written testimony, Adam Perryman, 3 pp**